Active Biotech AB Interim report January-June 2009

* Laquinimod -- BRAVO Phase III trial fully enrolled
* 57-57 -- explorative clinical trial initiated
* RhuDex(TM) -- preclinical tests in progress
* ANYARA -- Phase III trial fully enrolled
* TASQ -- Phase II trial fully enrolled
* ISI - target molecule for Q compounds published
* Net sales of SEK 5.2 M (5.8)
* Operating loss of SEK 118.5 M (loss: 104.7)
* Loss after tax of SEK 118.6 M (loss: 99.3)
* Loss per share for the period of SEK 2.22 (loss 2.07)
* Implemented rights issue contributed approximately SEK 249 M
* Number of shares at the end of the period (incl. warrants),
  65,052,238

For further information, please contact:
  Tomas Leanderson
  President and CEO
  Tel: +46 (0)46-19 20 95

  Göran Forsberg
  VP Investor Relations & Business Development

  Tel: +46 (0)46-19 11 54

  Hans
  Kolam
  CFO

  Tel: +46 (0)46-19 20 44



  Active Biotech AB
  (Corp. Reg. No. 556223-9227)
  PO Box 724, SE-220 07 Lund
  Sweden
  Tel: +46 (0)46-19 20 00
  Fax: +46 (0)46-19 11 00

  This report is also available at www.activebiotech.com
Active Biotech AB Interim report January-June 2009

Attachments
